About: Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Creator	Hoffmann, Hans-Heinrich Michailidis, Eleftherios Nussenzweig, Michel Rice, Charles Bieniasz, Paul Agudelo, Marianna Bednarski, Eva Caskey, Marina Cho, Alice Cipolla, Melissa Gaebler, Christian Gazumyan, Anna Hatziioannou, Theodora Lorenzi, Julio Mendoza, Pilar Muecksch, Frauke Robbiani, Davide Rutkowska, Magdalena Schmidt, Fabian Wang, Zijun Weisblum, Yiska
Source	BioRxiv; Medline; PMC; WHO
abstract	The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARSCoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1101/2020.06.08.140871
bibo:pmid	32577658
has license	cc-by-nc-nd
sha1sum (hex)	5318a20b30626fdaa50fb86eeda26614abf071cb
schema:url	https://doi.org/10.1101/2020.06.08.140871
resource representing a document's title	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
has PubMed Central identifier	PMC7302213
has PubMed identifier	32577658
schema:publication	bioRxiv
resource representing a document's body	covid:5318a20b30626fdaa50fb86eeda26614abf071cb#body_text
is schema:about of	named entity 'vaccination' named entity 'sensitivity' named entity 'infection' named entity 'VSV' named entity 'neutralizing' named entity 'virus' named entity 'While' named entity 'ANTIBODIES' named entity 'GENERATED' named entity 'EVALUATION' named entity 'VACCINATION' named entity 'virus' named entity 'describe' named entity 'SARS-CoV-2' named entity 'assay' named entity 'human monoclonal antibodies' named entity 'generated' named entity 'activity' named entity 'activity' named entity 'detected' named entity 'The' named entity 'convalescent plasma' named entity 'antiviral activity' named entity 'potency' named entity 'SARS-CoV-2' named entity 'serologic' named entity 'antibodies' named entity 'VSV' named entity 'HIV-1' named entity 'VSV' named entity 'viruses' named entity 'receptor' named entity 'flow cytometry' named entity 'infection' named entity 'Supernatant' named entity 'SARS-CoV-2' named entity 'HIV-1' named entity 'monoclonal antibodies' named entity 'technical replicates' named entity 'GFP' named entity 'expression levels' named entity 'supernatant' named entity 'supernatant' named entity 'therapeutic agents' named entity 'luciferase' named entity 'SARS-CoV-2' named entity 'protein' named entity 'human monoclonal antibodies' named entity 'Env' named entity 'C-terminus' named entity 'vector' named entity 'RBD' named entity 'VSV' named entity 'dynamic range' named entity 'VSV' named entity 'SARS-CoV-2' named entity 'formaldehyde' named entity 'pseudotyped viruses' named entity 'HIV' named entity 'human monoclonal antibodies' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software